Next Article in Journal
Empowering Women: Moving from Awareness to Action at the Immunology of Fungal Infections Gordon Research Conference
Next Article in Special Issue
Initiated Babesia ovata Sexual Stages under In Vitro Conditions Were Recognized by Anti-CCp2 Antibodies, Showing Changes in the DNA Content by Imaging Flow Cytometry
Previous Article in Journal
Risk Factors for Zoonotic Tuberculosis at the Wildlife–Livestock–Human Interface in South Africa
Previous Article in Special Issue
Interplay between Attenuation- and Virulence-Factors of Babesia bovis and Their Contribution to the Establishment of Persistent Infections in Cattle
Open AccessReview

Persistence of Babesia microti Infection in Humans

1
Johns Hopkins University School of Medicine; Baltimore, MD 21287, USA
2
Food and Drug Administration, Silver Spring, MD 20993, USA
3
Yale School of Public Health and Yale School of Medicine, New Haven, CT 06520 USA
*
Author to whom correspondence should be addressed.
Pathogens 2019, 8(3), 102; https://doi.org/10.3390/pathogens8030102
Received: 25 June 2019 / Revised: 12 July 2019 / Accepted: 13 July 2019 / Published: 17 July 2019
(This article belongs to the Special Issue Persistence in Babesia)
Persistent infection is a characteristic feature of babesiosis, a worldwide, emerging tick-borne disease caused by members of the genus Babesia. Persistence of Babesia infection in reservoir hosts increases the probability of survival and transmission of these pathogens. Laboratory tools to detect Babesia in red blood cells include microscopic detection using peripheral blood smears, nucleic acid detection (polymerase chain reaction and transcription mediated amplification), antigen detection, and antibody detection. Babesia microti, the major cause of human babesiosis, can asymptomatically infect immunocompetent individuals for up to two years. Chronically infected blood donors may transmit the pathogen to another person through blood transfusion. Transfusion-transmitted babesiosis causes severe complications and death in about a fifth of cases. Immunocompromised patients, including those with asplenia, HIV/AIDS, malignancy, or on immunosuppressive drugs, often experience severe disease that may relapse up to two years later despite anti-Babesia therapy. Persistent Babesia infection is promoted by Babesia immune evasive strategies and impaired host immune mechanisms. The health burden of persistent and recrudescent babesiosis can be minimized by development of novel therapeutic measures, such as new anti-parasitic drugs or drug combinations, improved anti-parasitic drug duration strategies, or immunoglobulin preparations; and novel preventive approaches, including early detection methods, tick-avoidance, and blood donor screening. View Full-Text
Keywords: Babesia; Babesia microti; persistence; recurrence; Plasmodia; malaria; spleen; blood transfusion Babesia; Babesia microti; persistence; recurrence; Plasmodia; malaria; spleen; blood transfusion
Show Figures

Figure 1

MDPI and ACS Style

Bloch, E.M.; Kumar, S.; Krause, P.J. Persistence of Babesia microti Infection in Humans. Pathogens 2019, 8, 102.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map

1
Back to TopTop